ALD403 is a novel monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine headache prevention. CGRP is involved in vasodilation and sensory transmission and is a validated target that is believed to play a key role in migraine headache. ALD403 is administered intravenously.

If you have a Hayes login, click here to view the full report on the Knowledge Center.